NP_004264.2
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
54,706 Da
NCBI Official Full Name
carbohydrate sulfotransferase 3
NCBI Official Synonym Full Names
carbohydrate (chondroitin 6) sulfotransferase 3
NCBI Protein Information
carbohydrate sulfotransferase 3; GST-0; C6ST-1; chondroitin 6-O-sulfotransferase 1; galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 0
UniProt Protein Name
Carbohydrate sulfotransferase 3
UniProt Synonym Protein Names
Chondroitin 6-O-sulfotransferase 1; C6ST-1; Chondroitin 6-sulfotransferase; Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 0; GST-0
UniProt Synonym Gene Names
UniProt Entry Name
CHST3_HUMAN
NCBI Summary for CHST3
This gene encodes an enzyme which catalyzes the sulfation of chondroitin, a proteoglycan found in the extracellular matrix and most cells which is involved in cell migration and differentiation. Mutations in this gene are associated with spondylepiphyseal dysplasia and humerospinal dysostosis. [provided by RefSeq, Mar 2009]
UniProt Comments for CHST3
CHST3: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the transfer of sulfate to position 6 of the N-acetylgalactosamine (GalNAc) residue of chondroitin. Chondroitin sulfate constitutes the predominant proteoglycan present in cartilage and is distributed on the surfaces of many cells and extracellular matrices. Can also sulfate Gal residues of keratan sulfate, another glycosaminoglycan, and the Gal residues in sialyl N- acetyllactosamine (sialyl LacNAc) oligosaccharides. May play a role in the maintenance of naive T-lymphocytes in the spleen. Defects in CHST3 are a cause of spondyloepiphyseal dysplasia with congenital joint dislocations (SEDC-JD). A bone dysplasia clinically characterized by dislocation of the knees and/or hips at birth, clubfoot, elbow joint dysplasia with subluxation and limited extension, short stature, and progressive kyphosis developing in late childhood. The disorder is usually evident at birth, with short stature and multiple joint dislocations or subluxations that dominate the neonatal clinical and radiographic picture. During childhood, the dislocations improve, both spontaneously and with surgical treatment, and features of spondyloepiphyseal dysplasia become apparent, leading to arthritis of the hips and spine with intervertebral disk degeneration, rigid kyphoscoliosis, and trunk shortening by late childhood. Belongs to the sulfotransferase 1 family. Gal/GlcNAc/GalNAc subfamily.
Protein type: Glycan Metabolism - chondroitin sulfate biosynthesis; Membrane protein, integral; EC 2.8.2.17; Transferase
Chromosomal Location of Human Ortholog: 10q22.1
Cellular Component: Golgi membrane; integral to membrane
Molecular Function: chondroitin 6-sulfotransferase activity; sulfotransferase activity; proteoglycan sulfotransferase activity
Biological Process: chondroitin sulfate metabolic process; sulfur metabolic process; chondroitin sulfate biosynthetic process; glycosaminoglycan metabolic process; carbohydrate metabolic process; T cell homeostasis; pathogenesis
Disease: Multiple Joint Dislocations, Short Stature, Craniofacial Dysmorphism, And Congenital Heart Defects; Spondyloepiphyseal Dysplasia With Congenital Joint Dislocations
Research Articles on CHST3
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Pathways associated with CHST3 elisa kit
Diseases associated with CHST3 elisa kit
Organs/Tissues associated with CHST3 elisa kit
|